In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation rate [ESR]) and group 3 (B-symptoms) received four cycles. Involved field radiotherapy (IFRT) 30 Gy was given after adequate chemotherapy response. Five-year overall survival and freedom from progression (FFP) were 96% (95% confidence interval [CI] 91-98%) and 90% (84-94%), respectively. Five-year FFP was 97% (90-99%), 89% (75-95%), and 73% (52-86%) for groups 1, 2, and 3, respectively. In patients with RF, chemotherapy responses of complete response unconfirmed (CRu), partial response (PR), and stable disease (SD) were associated with FFP of 90%, 86%, and 62% (p=0.17), and CR/no CR on functional imaging with FFP of 90%/67%, respectively (p=0.05). The 97% FFP in group 1 compares favorably with previously reported results from cooperative trial groups. Intensification of therapy warrants study in patients with RF and a poor chemotherapy response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2010.547155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-term outcome of hodgkin lymphoma patients and its prognostic factors in northeast peninsular Malaysia: A single centre experience.
Med J Malaysia
January 2025
Universiti Sains Malaysia, School of Medical Sciences, Department of Internal Medicine, Clinical Haematology Unit, 16150 Kubang Kerian, Kelantan, Malaysia.
Introduction: Hodgkin lymphoma (HL) is a hematopoietic malignancy characterized by the presence of Reed Sternberg cells, with generally favourable outcomes compared to other hematological malignancies. This study aims to determine the socio-demographic, clinical and treatment characteristics, as well as the short-term overall survival (OS) and progression-free survival (PFS) rates, of HL patients treated at Hospital Universiti Sains Malaysia (USM), a tertiary centre in northeast peninsular Malaysia.
Materials And Methods: We conducted a retrospective cohort study of HL patients treated from January 1, 2006, to December 31, 2018, with follow-up until December 31, 2021.
Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.
Am J Hematol
January 2025
Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Primary effusion lymphoma (PEL) is an HIV-associated B-cell non-Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There is no validated prognostic model in PEL, and prognosis is thought to be poor compared to other HIV-associated NHL. We derived the PEL-Prognostic score (PEL-PS) from an international real-world training set of 59 patients with HIV-associated PEL who received first-line anthracycline-containing chemotherapy from the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) in the United States and the National Center for HIV Malignancy at the Chelsea and Westminster Hospital (CWH) in England from 2000 to 2022.
View Article and Find Full Text PDFA Mitochondria-Related Signature in Diffuse Large B-Cell Lymphoma: Prognosis, Immune and Therapeutic Features.
Cancer Med
January 2025
Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
Background: Distinctive heterogeneity characterizes diffuse large B-cell lymphoma (DLBCL), one of the most frequent types of non-Hodgkin's lymphoma. Mitochondria have been demonstrated to be closely involved in tumorigenesis and progression, particularly in DLBCL.
Objective: The purposes of this study were to identify the prognostic mitochondria-related genes (MRGs) in DLBCL, and to develop a risk model based on MRGs and machine learning algorithms.
Primary lacrimal sac Burkitt lymphoma: A case report and literature review.
Am J Ophthalmol Case Rep
March 2025
Department of Ophthalmology, Hospital Sultan Idris Shah, Serdang, Malaysia.
Purpose: To highlight a case report of high-grade primary lacrimal sac Burkitt lymphoma in a young adult.
Observation: A 25-year-old gentleman was referred to the oculoplastic center for left eye medial canthal progressive swelling at the level below the medial canthal tendon for two months associated with tearing. He was initially treated for preseptal cellulitis but failed to respond to antibiotics.
Isolated Third Cranial Nerve Palsy As the Initial Presentation of Primary Central Nervous System Lymphoma: A Rare Case.
Cureus
December 2024
Department of Ophthalmology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, MYS.
This is an unusual case of primary central nervous system lymphoma (PCNSL) with isolated third cranial nerve palsy as the initial manifestation. Neurolymphomatosis (NL) is a rare manifestation of PCNSL. While NL is a rare manifestation of PCNSL, primary vitreoretinal lymphoma (PVRL) can be the presenting feature or a later-involved manifestation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!